Cargando…
Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience
INTRODUCTION: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus. MATERIAL AND METHODS: In this 12-week study, patients receiving twice-daily premixed insulin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811302/ https://www.ncbi.nlm.nih.gov/pubmed/33488849 http://dx.doi.org/10.5114/aoms.2020.93264 |
_version_ | 1783637469037592576 |
---|---|
author | Özçelik, Serhat Çelik, Mehmet Vural, Aşkı Aydın, Bünyamin Özçelik, Melike Gozu, Hulya |
author_facet | Özçelik, Serhat Çelik, Mehmet Vural, Aşkı Aydın, Bünyamin Özçelik, Melike Gozu, Hulya |
author_sort | Özçelik, Serhat |
collection | PubMed |
description | INTRODUCTION: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus. MATERIAL AND METHODS: In this 12-week study, patients receiving twice-daily premixed insulin therapy in group 1 (n = 55) were switched to twice-daily IDegAsp. In group 2 (n = 60), patients on intensive insulin therapy were switched to IDegAsp injected twice a day. Inter- and intragroup comparisons were made. RESULTS: A total of 115 patients were included in the study. There was a significant improvement in glycaemic control, median daily total insulin dose, body mass, body mass index, and hypoglycaemic events in group 1 and group 2 with the switch to IDegAsp (p < 0.05). The decrease in median daily total insulin dose requirement in group 2 was higher than that of group 1 (p = 0.001). There was no difference between groups in terms of other parameters (p > 0.05). CONCLUSIONS: The current analysis indicates that IDegAsp treatment improves outcomes, with the most notable differences observed in daily total insulin requirement, body mass, and hypoglycaemia. |
format | Online Article Text |
id | pubmed-7811302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-78113022021-01-22 Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience Özçelik, Serhat Çelik, Mehmet Vural, Aşkı Aydın, Bünyamin Özçelik, Melike Gozu, Hulya Arch Med Sci Clinical Research INTRODUCTION: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus. MATERIAL AND METHODS: In this 12-week study, patients receiving twice-daily premixed insulin therapy in group 1 (n = 55) were switched to twice-daily IDegAsp. In group 2 (n = 60), patients on intensive insulin therapy were switched to IDegAsp injected twice a day. Inter- and intragroup comparisons were made. RESULTS: A total of 115 patients were included in the study. There was a significant improvement in glycaemic control, median daily total insulin dose, body mass, body mass index, and hypoglycaemic events in group 1 and group 2 with the switch to IDegAsp (p < 0.05). The decrease in median daily total insulin dose requirement in group 2 was higher than that of group 1 (p = 0.001). There was no difference between groups in terms of other parameters (p > 0.05). CONCLUSIONS: The current analysis indicates that IDegAsp treatment improves outcomes, with the most notable differences observed in daily total insulin requirement, body mass, and hypoglycaemia. Termedia Publishing House 2020-02-25 /pmc/articles/PMC7811302/ /pubmed/33488849 http://dx.doi.org/10.5114/aoms.2020.93264 Text en Copyright: © 2020 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Clinical Research Özçelik, Serhat Çelik, Mehmet Vural, Aşkı Aydın, Bünyamin Özçelik, Melike Gozu, Hulya Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title | Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title_full | Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title_fullStr | Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title_full_unstemmed | Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title_short | Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
title_sort | outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811302/ https://www.ncbi.nlm.nih.gov/pubmed/33488849 http://dx.doi.org/10.5114/aoms.2020.93264 |
work_keys_str_mv | AT ozcelikserhat outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience AT celikmehmet outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience AT vuralaskı outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience AT aydınbunyamin outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience AT ozcelikmelike outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience AT gozuhulya outcomesoftransitionfrompremixedandintensiveinsulintherapiestoinsulinaspartdegludeccoformulationintype2diabetesmellitusarealworldexperience |